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Atherosclerosis is an inflammation-driven chronic disease of the arteries and the leading cause 
of death worldwide. Therefore, there is a growing need for efficient drug-testing and drug-
screening systems. Commonly used drug-testing technologies are based on two-dimensional 
cell culture systems, which cannot recapitulate in vivo conditions. On the other hand, animal 
models are not only lengthy and costly, but also poor predictors of human responses. To 
overcome these shortcomings, we have proposed to use organ-on-a-chip technology for 
atherosclerotic nanomedicine studies.  
We have developed a microfluidic chip consisting of two PDMS layers, separated by a 
polyester membrane. Each layer has a microfluidic channel, which is capable of simulating the 
shear condition of a vessel. In addition, endothelial cells were cultured on the membrane and 
then inflamed to mimic an atherosclerotic vessel. Calcein AM assay was used to investigate 
cell-viability and morphology of the cells. Moreover, Immunohistochemistry studies and 
permeation studies were performed. The results of these studies successfully showed tight 
junctions between cells before inflammation procedure, as well as compromised and leaky 
junctions after this procedure, which is the main indicator of inflamed vessels. Consequently, 
the proposed microfluidic chip, which mimics shear condition of a vessel and inflammatory 
condition of atherosclerosis, is a suitable alternative for typical atherosclerotic drug-screening 
systems. 
 
